Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 66, Issue 2, 2007, Pages 253-256

  Van Der Laken, C J ^a   Voskuyl, A E ^a   Roos, J C ^a   Stigter Van Walsum, M ^a   De Groot, E R ^b   Wolbink, G ^b   Dijkmans, B A C ^a   Aarden, L A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; DRUG ANTIBODY; INFLIXIMAB; METHOTREXATE; TECHNETIUM 99M;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; BLOOD ANALYSIS; CASE REPORT; COMPLEX FORMATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG LABELING; DRUG RESPONSE; FEMALE; HUMAN; IMAGING; ISOTOPE LABELING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOTOPE LABELING; JOINTS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SPLEEN; TECHNETIUM; TREATMENT FAILURE; WHOLE BODY IMAGING;

EID: 33846855387     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.057406     Document Type: Article

References (11)

1. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-03.
2. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594- 602.
3. Beart F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
4. Wolbink GJ, Vis M, Lems W, de Groot E, Nurmohamed MT, Stapel S, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15.
5. Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005;313:578-85.
6. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/Internal League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
7. 186Re using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med 1993;34:1953-63.
8. 186Re-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 1997;80:2360-70.
9. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.
10. Aalberse RC, van Loghem E, van Munster PJ, Nadorp JH. Human antibodies to IgE: a simple method to avoid ambiguous results of the radioimmunosorbent test (RIST). J Lab Clin Med 1974;83:831-9.
11. Aarden LA, de Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975;254:505- 15.